fda drug shortage semaglutide ends as sets deadline for compounders Semaglutide Injections and the FDA

FEBS J (2010) 277(23):481427

10.1016/j.molmet.2019.09.010 91 MuttenthalerM.KingG

Visible-to-NIR-light activated release: from small molecules to nanomaterials

ForePass is now advancing toward first-in-human clinical studies

Many patients report fewer cravings and feel more in control of food decisions after starting treatment

Here's the definitive quick reference: SIGNATURE TOXICITIES & ANTIDOTES: Cyclophosphamide = Hemorrhagic Cystitis MESNA (2-Mercaptoethane Sulfonate) Methotrexate = Myelosuppression Leucovorin (Folinic Acid) Rescue Doxorubicin = Cardiotoxicity Dexrazoxane (Cardioprotective) Cisplatin = Nephrotoxicity, Ototoxicity Amifostine (Cytoprotective) Bleomycin = Pulmonary Fibrosis (No antidote Prevention) Vincristine = Peripheral Neuropathy (No antidote Dose limiting) 5-FU = Palmar-Plantar Erythrodysesthesia (Hand-Foot Syndrome) CLASSIFICATION: Cell Cycle Specific: MTX (S), 5-FU (S), Vinca alkaloids (M), Taxanes (M) Cell Cycle Non-Specific: Cyclophosphamide, Doxorubicin, Cisplatin Mnemonic: "MESNA = Makes Cyclophosphamide Safe (NA)" One topic